lupus

News

Acute pain in a woman hand. Isolation on a white background

Hope for lupus sufferers with Feinstein Institutes-led phase...

Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research, have been published in the New England

News

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupu

News

Akili digital therapeutic shows promise in lupus patients

Akili looks like it could bring another digital therapeutic (DTx) to market after a clinical trial backed the efficacy of its AKL-T01 in patients with the autoimmune disorder systemic lupus

News

AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Be...

AstraZeneca's Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus (SLE) in the EU for more than 10 years.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

FDA approves AZ's anifrolumab, ending 10-year lupus drug dro...

AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus erythematosus (SLE) after claiming FDA approval for the drug as an add-on therapy for adults with the a

News

Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy

Hope for lupus sufferers with Feinstein Institutes-led phase...

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

Akili digital therapeutic shows promise in lupus patients

AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Be...

FDA approves AZ's anifrolumab, ending 10-year lupus drug dro...

Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

lupus

Editor's Picks